Elizabeth Cho-Fertikh, PhD is a scientist-turned-investor who is Managing Partner of MEDA Ventures, a healthcare venture capital group, which is currently on Fund II. MEDA Ventures sprung from MEDA Angels, angel investor group founded by physicians and scientists, through which 22 investments have been made including those out of its Fund 1, which has enjoyed a near 40% IRR for vintage year 2023. Of the 22 investments, there have been 2 exits and 0 shutdowns since inception in 2019. Elizabeth comes to the healthcare investment world with 30 years of cross-functional operational experience in drug development, digital health, regulatory affairs, clinical trials and business development at biotechs & startups (Macrogenics, RegenXBio, Enterin, VLP Therapeutics & Playbl).
She actively supports the innovation ecosystem by serving on the Executive Committee of Stand Up To Cancer, a nonprofit founded by Katie Couric, dedicated to supporting innovative R&D and advocacy efforts to advance cancer prevention, detection, treatment & awareness. She also serves as scientific/commercialization advisor to the National Cancer Institute’s Technology Transfer Office, as a reviewer of NCI SBIR grants and as a former investment committee member for the Virginia Commonwealth Health System. Elizabeth currently serves as an Investor Relations and Commercialization Advisor to two digital health startups and as a Board Observer of a cancer therapeutics startup.
Elizabeth received her BA from Johns Hopkins, her MS from Georgetown University, her PhD from Thomas Jefferson School of Medicine and completed her postdoctoral fellowship at Harvard Medical School & NIH.
